BR112023000500A2 - Partículas de sorafenibe e usos das mesmas - Google Patents

Partículas de sorafenibe e usos das mesmas

Info

Publication number
BR112023000500A2
BR112023000500A2 BR112023000500A BR112023000500A BR112023000500A2 BR 112023000500 A2 BR112023000500 A2 BR 112023000500A2 BR 112023000500 A BR112023000500 A BR 112023000500A BR 112023000500 A BR112023000500 A BR 112023000500A BR 112023000500 A2 BR112023000500 A2 BR 112023000500A2
Authority
BR
Brazil
Prior art keywords
particles
sorafenib
methods
sorafenib particles
ssa
Prior art date
Application number
BR112023000500A
Other languages
English (en)
Inventor
Sittenauer Jacob
Farthing Joseph
Williams Mark
Baltezor Michael
Dizerega Gere
Barreda Abarca Aranza
Clark Shelby
Original Assignee
Crititech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crititech Inc filed Critical Crititech Inc
Publication of BR112023000500A2 publication Critical patent/BR112023000500A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

PARTÍCULAS DE SORAFENIBE E USOS DAS MESMAS. Esta descrição prevê partículas de pelo menos 95% em peso de sorafenibe, ou um sal farmaceuticamente aceitável do mesmo, em que as partículas têm uma área superficial específica (SSA) de pelo menos 2 m2/g e têm um tamanho de partícula médio em distribuição de volume entre cerca de 0,7 µm e cerca de 8µm, métodos para seu uso, e métodos para produzir tais partículas.
BR112023000500A 2020-07-23 2021-07-21 Partículas de sorafenibe e usos das mesmas BR112023000500A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063055786P 2020-07-23 2020-07-23
PCT/US2021/042543 WO2022020449A1 (en) 2020-07-23 2021-07-21 Sorafenib particles and uses thereof

Publications (1)

Publication Number Publication Date
BR112023000500A2 true BR112023000500A2 (pt) 2023-01-31

Family

ID=77265349

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000500A BR112023000500A2 (pt) 2020-07-23 2021-07-21 Partículas de sorafenibe e usos das mesmas

Country Status (9)

Country Link
US (1) US20220241257A1 (pt)
EP (1) EP4185289A1 (pt)
JP (1) JP2023535028A (pt)
KR (1) KR20230044422A (pt)
CN (1) CN115916198A (pt)
AU (1) AU2021311602A1 (pt)
BR (1) BR112023000500A2 (pt)
CA (1) CA3183486A1 (pt)
WO (1) WO2022020449A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11738014B2 (en) 2021-11-10 2023-08-29 Crititech, Inc. Niraparib particles and uses thereof
US11738029B2 (en) 2021-11-10 2023-08-29 Crititech, Inc. Rucaparib particles and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1419883A (en) 1982-05-04 1983-11-10 Geoffrey Lester Harding Solar energy collector system
US4704713A (en) 1985-12-26 1987-11-03 Bell Communications Research, Inc. Optical ring network
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
WO2007053573A2 (en) * 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
US20080213374A1 (en) * 2006-07-10 2008-09-04 Elan Pharma International Limited Nanoparticulate sorafenib formulations
PT108368B (pt) * 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
JP6921759B2 (ja) * 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド 捕集装置および使用法
WO2018170210A1 (en) * 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
CA3022777A1 (en) * 2017-04-21 2018-10-25 Bio-Synectics Inc. Method for preparing nanoparticle of active ingredient using lipid as lubricant in milling process
KR102184117B1 (ko) * 2017-10-31 2020-11-30 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법
US20220024777A1 (en) * 2018-11-07 2022-01-27 Disruptive Materials Pharma Ab Novel amorphous active pharmaceutical ingredients comprising substantially amorphous mesoporous magnesium carbonate

Also Published As

Publication number Publication date
CA3183486A1 (en) 2022-01-27
KR20230044422A (ko) 2023-04-04
JP2023535028A (ja) 2023-08-15
WO2022020449A1 (en) 2022-01-27
AU2021311602A1 (en) 2023-01-05
EP4185289A1 (en) 2023-05-31
US20220241257A1 (en) 2022-08-04
CN115916198A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
BR112023000501A2 (pt) Partículas de lapatinibe e usos das mesmas
BR112023000500A2 (pt) Partículas de sorafenibe e usos das mesmas
BR112017020767A2 (pt) artigo abrasivo revestido e método para fabricação do mesmo
BRPI0508077A (pt) produto de suspensão para reduzir umidade embaixo do braço
BRPI0409410A (pt) material em partìcula contendo elastÈmero termoplástico e métodos para fabricação e uso do mesmo
BR112019001331B8 (pt) Chapa de aço
BR112014007089A2 (pt) artigos abrasivos incluindo materiais de partículas abrasivas, abrasivos revestidos usando os materiais de partículas abrasivas e os métodos de formação
BR0309148A (pt) Composição de revestimento, método para transmitir resistência à abrasão a assoalhos e a um substrato, e, assoalho de madeira ou de vinilo
BR112016008016A2 (pt) inibidores de kras g12c
WO2014086750A3 (en) Composition comprising a biological control agent and an insecticide
BRPI0411340A (pt) conservante particulado de madeira e método para produzir o mesmo
BR112018013724A2 (pt) materiais de construção de compósito particulado
BR112018068812A2 (pt) método para a produção de água potável
BR112015023117A2 (pt) composições de agente ativo retinóide particulado fino seco e formulações tópicas incluindo as mesmas
Diler et al. The novel surfactant protein SP-H enhances the phagocytosis efficiency of macrophage-like cell lines U937 and MH-S
BR112018072768A2 (pt) suspensão, composição farmacêutica, método para formar uma suspensão fulvestrant aquosa, suspensão fulvestrant aquosa e método para tratar um indivíduo tendo câncer de mama
BRPI0614080A2 (pt) Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose
CN104018594B (zh) 一种球面调谐质量阻尼器减振控制装置
AR061262A1 (es) Metodo para tratar trastornos respiratorios uso de un antibiotico enla fabricacion de un aerosol y composicion de antibiotico en aerosol
BRPI0418475A (pt) composição removedora de noxx para uso como revestimento translúcido sobre uma superfìcie de material de construção, e, método para conferir propriedade de auto-limpeza para contaminantes atmosféricos na superfìcie de um material
BR112023020450A2 (pt) Anticorpos anti-cd19 e estruturas car-t
BR0312131A (pt) Formulações em pó
BR0011429A (pt) Métodos para o revestimento de partìculas e partìculas produzidas pelos mesmos
BR102019026799A8 (pt) Método e sistema para reduzir desgaste de freio de aeronave
BR0313127A (pt) Produto de pigmento, método para fabricar o mesmo, composição de revestimento, e, método para formar um revestimento brilhante sobre papel